Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/taming-the-dragon-genomic-biomarkers-to-individualize-the-treatment-of-uoELh3MO02
References (129)
-
K. Pantel, C. Alix-Panabières (2010)
Circulating tumour cells in cancer patients: challenges and perspectives.Trends in molecular medicine, 16 9
-
J. Barretina, B. Taylor, S. Banerji, A. Ramos, M. Lagos‐Quintana, Penelope Decarolis, K. Shah, N. Socci, B. Weir, Alan Ho, Derek Chiang, B. Reva, C. Mermel, G. Getz, Yevgenyi Antipin, R. Beroukhim, John Major, C. Hatton, Richard Nicoletti, M. Hanna, Ted Sharpe, T. Fennell, K. Cibulskis, R. Onofrio, Tsuyoshi Saito, N. Shukla, C. Lau, Sven Nelander, S. Silver, C. Sougnez, A. Viale, W. Winckler, R. Maki, L. Garraway, A. Lash, H. Greulich, D. Root, W. Sellers, G. Schwartz, C. Antonescu, E. Lander, H. Varmus, M. Ladanyi, C. Sander, M. Meyerson, S. Singer (2010)
Subtype-specific genomic alterations define new targets for soft tissue sarcoma therapyNature genetics, 42
-
W. Roock, B. Claes, David Bernasconi, J. Schutter, B. Biesmans, G. Fountzilas, K. Kalogeras, V. Kotoula, D. Papamichael, P. Laurent-Puig, F. Penault-Llorca, P. Rougier, B. Vincenzi, D. Santini, G. Tonini, F. Cappuzzo, M. Frattini, F. Molinari, P. Saletti, S. Dosso, M. Martini, A. Bardelli, S. Siena, A. Sartore-Bianchi, J. Tabernero, T. Macarulla, F. Fioré, A. Gangloff, F. Ciardiello, P. Pfeiffer, C. Qvortrup, T. Hansen, E. Cutsem, H. Piessevaux, D. Lambrechts, M. Delorenzi, S. Tejpar (2010)
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.The Lancet. Oncology, 11 8
-
P. Fong, D. Boss, T. Yap, A. Tutt, P. Wu, M. Mergui-Roelvink, Peter Mortimer, H. Swaisland, A. Lau, M. O’Connor, A. Ashworth, J. Carmichael, S. Kaye, J. Schellens, J. Bono (2009)
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.The New England journal of medicine, 361 2
-
W. Pao, Theresa Wang, Gregory Riely, V. Miller, Qiulu Pan, M. Ladanyi, M. Zakowski, R. Heelan, M. Kris, H. Varmus (2005)
KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or ErlotinibPLoS Medicine, 2
-
Y. Lo, R. Chiu (2009)
Next-generation sequencing of plasma/serum DNA: an emerging research and molecular diagnostic tool.Clinical chemistry, 55 4
-
P. Borst, L. Wessels (2010)
Do predictive signatures really predict response to cancer chemotherapy?Cell Cycle, 9
-
K. Flaherty, I. Puzanov, Kevin Kim, A. Ribas, G. McArthur, J. Sosman, P. O'dwyer, Richard Lee, J. Grippo, K. Nolop, P. Chapman (2010)
Inhibition of mutated, activated BRAF in metastatic melanoma.The New England journal of medicine, 363 9
-
K. Hede (2008)
Breast cancer testing scandal shines spotlight on black box of clinical laboratory testing.Journal of the National Cancer Institute, 100 12
-
F. Nkoy, M. Hammond, W. Rees, T. Belnap, B. Rowley, Steve Catmull, W. Sause (2010)
Variable specimen handling affects hormone receptor test results in women with breast cancer: a large multihospital retrospective study.Archives of pathology & laboratory medicine, 134 4
-
A. Gnirke, Alexandre Melnikov, J. Maguire, Peter Rogov, E. Leproust, W. Brockman, T. Fennell, G. Giannoukos, Sheila Fisher, C. Russ, S. Gabriel, D. Jaffe, E. Lander, C. Nusbaum (2009)
Solution Hybrid Selection with Ultra-long Oligonucleotides for Massively Parallel Targeted SequencingNature biotechnology, 27
-
J. Hoskins, L. Carey, H. McLeod (2009)
CYP2D6 and tamoxifen: DNA matters in breast cancerNature Reviews Cancer, 9
-
Sohrab Shah, Ryan Morin, J. Khattra, Leah Prentice, Trevor Pugh, A. Burleigh, Allen Delaney, K. Gelmon, Ryan Guliany, J. Senz, C. Steidl, R. Holt, Steven Jones, Mark Sun, G. Leung, Richard Moore, T. Severson, G. Taylor, A. Teschendorff, Kane Tse, G. Turashvili, R. Varhol, R. Warren, P. Watson, Yongjun Zhao, C. Caldas, D. Huntsman, M. Hirst, M. Marra, S. Aparicio (2009)
Mutational evolution in a lobular breast tumour profiled at single nucleotide resolutionNature, 461
-
E. Pleasance, R. Cheetham, P. Stephens, D. Mcbride, S. Humphray, C. Greenman, I. Varela, Meng‐Lay Lin, G. Ordóñez, G. Bignell, K. Ye, J. Alipaz, Markus Bauer, D. Beare, A. Butler, Richard Carter, Lina Chen, A. Cox, S. Edkins, P. Kokko-Gonzales, N. Gormley, R. Grocock, C. Haudenschild, Matthew Hims, Terena James, Mingming Jia, Z. Kingsbury, Catherine Leroy, J. Marshall, A. Menzies, L. Mudie, Z. Ning, Tom Royce, Ole Schulz-Trieglaff, Anastassia Spiridou, L. Stebbings, L. Szajkowski, J. Teague, David Williamson, L. Chin, M. Ross, Peter Campbell, D. Bentley, P. Futreal, Michael Stratton (2010)
A comprehensive catalogue of somatic mutations from a human cancer genomeNature, 463
-
D. Mcbride, A. Orpana, C. Sotiriou, H. Joensuu, P. Stephens, L. Mudie, E. Hämäläinen, L. Stebbings, L. Andersson, A. Flanagan, V. Durbecq, M. Ignatiadis, O. Kallioniemi, C. Heckman, K. Alitalo, H. Edgren, P. Futreal, M. Stratton, P. Campbell (2010)
Use of cancer‐specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumorsGenes, 49
-
R. Neve, K. Chin, J. Fridlyand, Jennifer Yeh, F. Baehner, T. Fevr, Laura Clark, N. Bayani, Jean-Philippe Coppé, F. Tong, T. Speed, P. Spellman, S. Devries, A. Lapuk, Nicholas Wang, W. Kuo, J. Stilwell, D. Pinkel, D. Albertson, F. Waldman, F. McCormick, R. Dickson, Michael Johnson, M. Lippman, S. Ethier, A. Gazdar, J. Gray (2006)
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.Cancer cell, 10 6
-
G. Demetri, M. Mehren, C. Blanke, A. Abbeele, B. Eisenberg, P. Roberts, M. Heinrich, D. Tuveson, S. Singer, M. Janicek, J. Fletcher, S. Silverman, S. Silberman, R. Capdeville, B. Kiese, B. Peng, S. Dimitrijević, B. Druker, C. Corless, C. Fletcher, H. Joensuu (2002)
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.The New England journal of medicine, 347 7
-
F. Bibeau, E. Lopez-Crapez, F. Fioré, S. Thézénas, M. Ychou, F. Blanchard, A. Lamy, F. Penault-Llorca, T. Frebourg, P. Michel, J. Sabourin, F. Boissière-Michot (2009)
Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 7
-
Y. Choi, M. Soda, Y. Yamashita, Toshihide Ueno, Junpei Takashima, T. Nakajima, Y. Yatabe, K. Takeuchi, T. Hamada, H. Haruta, Y. Ishikawa, H. Kimura, T. Mitsudomi, Y. Tanio, H. Mano (2010)
EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.The New England journal of medicine, 363 18
-
D. Parsons, Siân Jones, Xiaosong Zhang, Jimmy Lin, R. Leary, P. Angenendt, P. Mankoo, H. Carter, I. Siu, G. Gallia, A. Olivi, R. McLendon, B. Rasheed, S. Keir, T. Nikolskaya, Y. Nikolsky, D. Busam, H. Tekleab, L. Diaz, James Hartigan, Douglas Smith, R. Strausberg, S. Marie, S. Shinjo, Hai Yan, G. Riggins, D. Bigner, R. Karchin, N. Papadopoulos, G. Parmigiani, B. Vogelstein, V. Velculescu, K. Kinzler (2008)
An Integrated Genomic Analysis of Human Glioblastoma MultiformeScience, 321
-
Jun Lu, G. Getz, E. Miska, Ezequiel Alvarez-Saavedra, J. Lamb, David Peck, A. Sweet-Cordero, B. Ebert, Raymond Mak, A. Ferrando, J. Downing, T. Jacks, H. Horvitz, T. Golub (2005)
MicroRNA expression profiles classify human cancersNature, 435
-
A. Moritz, Y. Li, A. Guo, J. Villén, Yi Wang, J. Macneill, J. Kornhauser, K. Sprott, Jing Zhou, A. Possemato, J. Ren, P. Hornbeck, L. Cantley, S. Gygi, J. Rush, M. Comb (2010)
Akt–RSK–S6 Kinase Signaling Networks Activated by Oncogenic Receptor Tyrosine KinasesScience Signaling, 3
-
L. Ding, G. Getz, D. Wheeler, E. Mardis, M. McLellan, K. Cibulskis, C. Sougnez, H. Greulich, D. Muzny, M. Morgan, L. Fulton, R. Fulton, Qunyuan Zhang, M. Wendl, M. Lawrence, D. Larson, Ken Chen, D. Dooling, A. Sabo, A. Hawes, Hua Shen, S. Jhangiani, L. Lewis, O. Hall, Yiming Zhu, T. Mathew, Yanru Ren, Jiqiang Yao, S. Scherer, Kerstin Clerc, G. Metcalf, Brian Ng, A. Milosavljevic, M. Gonzalez-Garay, John Osborne, R. Meyer, Xiaoqi Shi, Yuzhu Tang, D. Koboldt, Ling Lin, R. Abbott, T. Miner, C. Pohl, G. Fewell, C. Haipek, Heather Schmidt, Brian Dunford-Shore, A. Kraja, S. Crosby, Christopher Sawyer, T. Vickery, Sacha Sander, J. Robinson, W. Winckler, J. Baldwin, L. Chirieac, A. Dutt, T. Fennell, M. Hanna, B. Johnson, R. Onofrio, Roman Thomas, G. Tonon, B. Weir, Xiaojun Zhao, L. Ziaugra, M. Zody, T. Giordano, M. Orringer, J. Roth, M. Spitz, I. Wistuba, B. Ozenberger, P. Good, A. Chang, D. Beer, M. Watson, M. Ladanyi, S. Broderick, A. Yoshizawa, W. Travis, W. Pao, M. Province, G. Weinstock, H. Varmus, S. Gabriel, E. Lander, R. Gibbs, M. Meyerson, R. Wilson (2008)
Somatic mutations affect key pathways in lung adenocarcinomaNature, 455
-
Siân Jones, Xiaosong Zhang, D. Parsons, Jimmy Lin, R. Leary, P. Angenendt, P. Mankoo, H. Carter, H. Kamiyama, A. Jimeno, Seung‐Mo Hong, Baojin Fu, Ming-Tseh Lin, E. Calhoun, M. Kamiyama, K. Walter, T. Nikolskaya, Y. Nikolsky, James Hartigan, Douglas Smith, M. Hidalgo, S. Leach, A. Klein, E. Jaffee, M. Goggins, A. Maitra, C. Iacobuzio-Donahue, J. Eshleman, S. Kern, R. Hruban, R. Karchin, N. Papadopoulos, G. Parmigiani, B. Vogelstein, V. Velculescu, K. Kinzler (2008)
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic AnalysesScience, 321
-
A. Ashworth (2008)
A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 22
-
Cristina Arzabe, Valéria Costa, Helena Alves, Alba Leonor, Silva Martins, Ynaiá Bueno (2009)
Challenges and perspectives -
D. Etemadmoghadam, A. deFazio, R. Beroukhim, C. Mermel, J. George, G. Getz, R. Tothill, A. Okamoto, M. Raeder, P. Harnett, S. Lade, L. Akslen, A. Tinker, Bianca Locandro, K. Alsop, Y. Chiew, N. Traficante, S. Fereday, Daryl Johnson, S. Fox, W. Sellers, M. Urashima, H. Salvesen, M. Meyerson, D. Bowtell (2009)
Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian CarcinomasClinical Cancer Research, 15
-
J. Sparano (2006)
TAILORx: trial assigning individualized options for treatment (Rx).Clinical breast cancer, 7 4
-
(2010)
A small-cell lung cancer genome with complex signatures of tobacco exposure -
J. Koivunen, C. Mermel, K. Zejnullahu, C. Murphy, E. Lifshits, A. Holmes, H. Choi, Jhingook Kim, Derek Chiang, Roman Thomas, Jinseon Lee, W. Richards, D. Sugarbaker, C. Ducko, N. Lindeman, J. Marcoux, J. Engelman, N. Gray, Charles Lee, M. Meyerson, P. Jänne (2008)
EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung CancerClinical Cancer Research, 14
-
C. Creighton, Xiaoyong Fu, Bryan Hennessy, Angelo Casa, Yiqun Zhang, A. González-Angulo, A. Lluch, Joe Gray, Joe Gray, PH Brown, S. Hilsenbeck, C. Osborne, Gordon Mills, Adrian Lee, R. Schiff (2010)
Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancerBreast Cancer Research : BCR, 12
-
E. Iorns, N. Turner, R. Elliott, N. Syed, O. Garrone, M. Gasco, A. Tutt, T. Crook, C. Lord, A. Ashworth (2008)
Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer.Cancer cell, 13 2
-
R. Levine, M. Wadleigh, J. Cools, B. Ebert, G. Wernig, B. Huntly, T. Boggon, I. Wlodarska, Jennifer Clark, Sandra Moore, Jennifer Adelsperger, Sumin Koo, Jeffrey Lee, S. Gabriel, T. Mercher, A. D’Andrea, S. Fröhling, K. Döhner, P. Marynen, P. Vandenberghe, R. Mesa, A. Tefferi, J. Griffin, M. Eck, W. Sellers, M. Meyerson, T. Golub, Stephanie Lee, D. Gilliland (2005)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.Cancer cell, 7 4
-
B. Weir, M. Woo, G. Getz, S. Perner, L. Ding, R. Beroukhim, William Lin, M. Province, A. Kraja, L. Johnson, K. Shah, Mitsuo Sato, Roman Thomas, J. Barletta, I. Borecki, S. Broderick, A. Chang, Derek Chiang, L. Chirieac, Jeonghee Cho, Y. Fujii, A. Gazdar, T. Giordano, H. Greulich, M. Hanna, B. Johnson, M. Kris, A. Lash, Ling Lin, N. Lindeman, E. Mardis, J. McPherson, J. Minna, M. Morgan, M. Nadel, M. Orringer, John Osborne, B. Ozenberger, A. Ramos, James Robinson, J. Roth, V. Rusch, H. Sasaki, F. Shepherd, C. Sougnez, M. Spitz, M. Tsao, David Twomey, R. Verhaak, G. Weinstock, D. Wheeler, W. Winckler, A. Yoshizawa, Soyoung Yu, M. Zakowski, Qunyuan Zhang, D. Beer, I. Wistuba, M. Watson, L. Garraway, M. Ladanyi, W. Travis, W. Pao, M. Rubin, S. Gabriel, R. Gibbs, H. Varmus, R. Wilson, E. Lander, M. Meyerson (2007)
Characterizing the cancer genome in lung adenocarcinomaNature, 450
-
S. Maheswaran, L. Sequist, S. Nagrath, L. Ulkus, Brian Brannigan, Chey Collura, Elizabeth Inserra, S. Diederichs, A. Iafrate, D. Bell, S. Digumarthy, A. Muzikansky, A. Muzikansky, D. Irimia, J. Settleman, R. Tompkins, Ronald Tompkins, T. Lynch, M. Toner, M. Toner, D. Haber, D. Haber (2008)
Detection of mutations in EGFR in circulating lung-cancer cells.The New England journal of medicine, 359 4
-
J. Paez, P. Jänne, Jeffrey Lee, Sean Tracy, H. Greulich, S. Gabriel, P. Herman, F. Kaye, N. Lindeman, T. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M. Eck, W. Sellers, B. Johnson, M. Meyerson (2004)
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 304
-
U. McDermott, A. Iafrate, N. Gray, T. Shioda, M. Classon, S. Maheswaran, Wenjun Zhou, H. Choi, Shannon Smith, L. Dowell, L. Ulkus, Georgiana Kuhlmann, Patricia Greninger, J. Christensen, D. Haber, J. Settleman (2008)
Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.Cancer research, 68 9
-
N. Turner, A. Tutt, A. Ashworth (2005)
Targeting the DNA repair defect of BRCA tumours.Current opinion in pharmacology, 5 4
-
J. Durant, P. Clevenbergh, P. Halfon, P. Delgiudice, S. Porsin, P. Simonet, N. Montagne, C. Boucher, J. Schapiro, P. Dellamonica (1999)
Drug-resistance genotyping in HIV-1 therapy: the VIRAD APT randomi sed controlled trialThe Lancet, 353
-
K. Berns, H. Horlings, B. Hennessy, M. Madiredjo, E. Hijmans, K. Beelen, S. Linn, A. González-Angulo, K. Stemke‐Hale, M. Hauptmann, R. Beijersbergen, G. Mills, M. Vijver, R. Bernards (2007)
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.Cancer cell, 12 4
-
N. Shah, B. Skaggs, S. Branford, T. Hughes, J. Nicoll, R. Paquette, C. Sawyers (2007)
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.The Journal of clinical investigation, 117 9
-
Adam Lee, H. Ezzeldin, J. Fourie, R. Diasio (2004)
Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy.Clinical advances in hematology & oncology : H&O, 2 8
-
V. Jordan (2003)
Tamoxifen: a most unlikely pioneering medicineNature Reviews Drug Discovery, 2
-
D. Cameron, M. Casey, M. Press, D. Lindquist, T. Pieńkowski, C. Romieu, S. Chan, A. Jagiełło-Gruszfeld, B. Kaufman, J. Crown, A. Chan, M. Campone, P. Viens, N. Davidson, V. Gorbounova, J. Raats, D. Skarlos, B. Newstat, D. Roychowdhury, P. Paoletti, C. Oliva, S. Rubin, S. Stein, C. Geyer (2008)
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analysesBreast Cancer Research and Treatment, 112
-
L. Ding, M. Ellis, Shunqiang Li, D. Larson, Ken Chen, J. Wallis, C. Harris, M. McLellan, R. Fulton, L. Fulton, R. Abbott, J. Hoog, D. Dooling, D. Koboldt, Heather Schmidt, Joelle Kalicki, Qunyuan Zhang, Lei Chen, Ling Lin, M. Wendl, Joshua McMichael, V. Magrini, L. Cook, S. McGrath, T. Vickery, Elizabeth Appelbaum, K. Deschryver, S. Davies, Therese Guintoli, Li Lin, R. Crowder, Y. Tao, J. Snider, Scott Smith, Adam Dukes, Gabriel Sanderson, C. Pohl, K. Delehaunty, C. Fronick, Kimberley Pape, Jerry Reed, J. Robinson, J. Hodges, W. Schierding, N. Dees, D. Shen, D. Locke, Madeline Wiechert, James Eldred, Joshua Peck, Benjamin Oberkfell, Justin Lolofie, Feiyu Du, Amy Hawkins, M. O'Laughlin, Kelly Bernard, M. Cunningham, Glendoria Elliott, M. Mason, Dominic Thompson, J. Ivanovich, P. Goodfellow, C. Perou, G. Weinstock, R. Aft, M. Watson, T. Ley, R. Wilson, E. Mardis (2010)
Genome Remodeling in a Basal-like Breast Cancer Metastasis and XenograftNature, 464
-
H. Gómez, D. Doval, M. Chavez, P. Ang, Z. Aziz, S. Nag, C. Ng, S. Franco, L. Chow, M. Arbushites, M. Casey, M. Berger, S. Stein, G. Sledge (2008)
Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 18
-
T. Lynch, D. Bell, Raffaella Sordella, S. Gurubhagavatula, R. Okimoto, Brian Brannigan, Patricia Harris, Sara Haserlat, J. Supko, F. Haluska, D. Louis, D. Christiani, J. Settleman, D. Haber (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.The New England journal of medicine, 350 21
-
L. Saal, P. Johansson, K. Holm, Sofia Gruvberger-Saal, Q. She, M. Maurer, Susan Koujak, A. Ferrando, P. Malmström, L. Memeo, J. Isola, P. Bendahl, N. Rosen, H. Hibshoosh, M. Ringnér, Å. Borg, R. Parsons (2007)
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activityProceedings of the National Academy of Sciences, 104
-
J. Asara (2010)
Faculty Opinions recommendation of Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors. -
M. Moroni, S. Veronese, S. Benvenuti, G. Marrapese, A. Sartore-Bianchi, F. Nicolantonio, M. Gambacorta, S. Siena, A. Bardelli (2005)
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.The Lancet. Oncology, 6 5
-
A. Sartore-Bianchi, M. Martini, F. Molinari, S. Veronese, M. Nichelatti, S. Artale, F. Nicolantonio, P. Saletti, S. Dosso, L. Mazzucchelli, M. Frattini, S. Siena, A. Bardelli (2009)
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.Cancer research, 69 5
-
O. Abe, R. Abe, K. Enomoto, K. Kikuchi, H. Koyama, H. Masuda, Y. Nomura, K. Sakai, K. Sugimachi, T. Tominaga, J. Uchino, M. Yoshida, J. Haybittle, C. Davies, V. Harvey, TM Holdaway, R. Kay, B. Mason, J. Forbes, N. Wilcken, M. Gnant, R. Jakesz, M. Ploner, H. Yosef, C. Focan, J. Lobelle, U. Peek, G. Oates, J. Powell, M. Durand, L. Mauriac, A. Leo, S. Dolci, M. Piccart, M. Masood, D. Parker, J. Price, P. Hupperets, S. Jackson, J. Ragaz, D. Berry, G. Broadwater, C. Cirrincione, H. Muss, L. Norton, R. Weiss, H. Abu‐Zahra, S. Portnoj, M. Baum, J. Cuzick, J. Houghton, D. Riley, NH Gordon, H. Davis, A. Beatrice, J. Mihura, A. Naja, Y. Lehingue, P. Romestaing, JB Dubois, T. Delozier, J. Macé-Lesec’h, P. Rambert, O. Andrysek, J. Barkmanova, Owen, P. Meier, A. Howell, G. Ribeiro, R. Swindell, R. Alison, J. Boreham, M. Clarke, R. Collins, S. Darby, P. Elphinstone, Evans, J. Godwin, R. Gray, C. Harwood, C. Hicks, S. James, E. Mackinnon, P. Mcgale, T. McHugh, G. Mead, R. Peto, Y. Wang, J. Albano, Cf Oliveira, H. Gervásio, J. Gordilho, H. Johansen, H. Mouridsen, R. Gelman, Harris, I. Henderson, Claire Shapiro, K. Andersen, C. Axelsson, M. Blichert‐Toft, S. Møller, J. Overgaard, M. Overgaard, C. Rose, B. Cartensen, T. Palshof, H. Trampisch, O. Dalesio, D. Vries, S. Rodenhuis, H. Tinteren, R. Comis, N. Davidson, N. Robert, G. Sledge, D. Tormey, W. Wood, D. Cameron, U. Chetty, P. Forrest, W. Jack, J. Rossbach, J. Klijn, A. Treurniet‐Donker, W. Putten, Alberto Costa, U. Veronesi, H. Bartelink, L. Duchateau, C. Legrand, R. Sylvester, J. Hage, C. Velde, M. Cunningham, R. Catalano, R. Creech, J. Bonneterre, P. Fargeot, P. Fumoleau, P. Kerbrat, M. Namer, W. Jonat, M. Kaufmann, M. Schumacher, G. Minckwitz, G. Bastert, H. Rauschecker, R. Sauer, W. Sauerbrei, A. Schauer, A. Schryver, L. Vakaet, M. Belfiglio, A. Nicolucci, F. Pellegrini, M. Sacco, M. Valentini, C. McArdle, D. Smith, E. Galligioni, F. Boccardo, A. Rubagotti, D. Dent, C. Gudgeon, A. Hacking, A. Erazo, J. Medina, M. Izuo, Y. Morishita, H. Takei, I. Fentiman, J. Hayward, R. Rubens, D. Skilton, H. Graeff, F. Jänicke, C. Meisner, H. Scheurlen, D. Fournier, U. Dafni, G. Fountzilas, P. Klefstrom, C. Blomqvist, T. Saarto, R. Margreiter, B. Asselain, R. Salmon, Vilcoq, R. Arriagada, C. Hill, A. Laplanche, M. Lê, M. Spielmann, P. Bruzzi, E. Montanaro, R. Rosso, Sertoli, M. Venturini, D. Amadori, J. Benraadt, M. Kooi, A. Velde, J. Dongen, J. Vermorken, M. Castiglione, F. Cavalli, A. Coates, J. Collins, J. Forbes, R. Gelber, A. Goldhirsch, J. Lindtner, K. Price, C. Rudenstam, H. Senn, J. Bliss, C. Chilvers, R. Coombes, E. Hall, M. Marty, R. Borovik, G. Brufman, H. Hayat, E. Robinson, N. Wigler, G. Bonadonna, T. Camerini, G. Palo, M. Vecchio, F. Formelli, P. Valagussa, A. Martoni, F. Pannuti, G. Cocconi, A. Colozza, R. Camisa, K. Aogi, S. Takashima, T. Ikeda, K. Inokuchi, K. Sawa, H. Sonoo, S. Korzeniowski, J. Skołyszewski, M. Ogawa, J. Yamashita, J. Bonté, R. Christiaens, R. Paridaens, W. Boegart, P. Martin, S. Romain, T. Hakes, C. Hudis, R. Wittes, G. Giokas, D. Kondylis, B. Lissaios, R. Huerta, MG Sainz, R. Altemus, K. Cowan, D. Danforth, A. Lichter, M. Lippman, J. O’Shaughnessy, L. Pierce, S. Steinberg, D. Venzon, J. Zujewski, A. Paradiso, M. Lena, F. Schittulli, J. Myles, J. Pater, K. Pritchard, S. Anderson, G. Bass, Andrew Brown, J. Bryant, J. Costantino, J. Dignam, B. Fisher, C. Redmond, S. Wieand, N. Wolmark, I. Jackson, M. Palmer, J. Ingle, V. Suman, N. Bengtsson, H. Jonsson, L. Larsson, J. Lythgoe, M. Kissin, B. Erikstein, E. Hannisdal, Abby Jacobsen, J. Varhaug, S. Gundersen, M. Hauer-Jensen, H. Høst, R. Nissen-Meyer, R. Blamey, A. Mitchell, D. Morgan, J. Robertson, M. Palma, G. Mathé, J. Misset, R. Clark, M. Levine, K. Morimoto, Y. Takatsuka, E. Crossley, A. Harris, D. Talbot, Marianne Taylor, B. Blasio, Ivanov, Semiglazov, J. Brockschmidt, Cooper, H. Ueo, C. Falkson, R. a'Hern, S. Ashley, T. Powles, I. Smith, Yarnold, Gazet Jc, N. Cocoran, N. Deshpande, L. Martino, P. Douglas, A. Lindtner, G. Notter, Ajs Bryant, G. Ewing, L. Firth, J. Krushen-Kosloski, L. Foster, W. George, H. Stewart, P. Stroner, P. Malmström, T. Möller, S. Rydén, Tengrup, L. Tennvall-Nittby, J. Carstenssen, M. Dufmats, T. Hatschek, B. Nordenskjöld, M. Söderberg, J. Carpenter, K. Albain, James Crowley, S. Green, S. Martino, C. Osborne, P. Ravdin, U. Glas, U. Johansson, L. Rutqvist, T. Singnomklao, A. Wallgren, R. Maibach, B. Thürlimann, H. Brenner, A. Hercbergs, M. Yoshimoto, G. Deboer, A. Paterson, J. Meakin, T. Panzarella, Y. Shan, Y. Shao, Y Wang, DB Zhao, Zm Chen, HC Pan, J. Bahi, M. Reid, M. Spittle, Gp Deutsch, F. Senanayake, D. Kwong, A. Bianco, C. Carlomagno, M. Laurentiis, S. Placido, A. Buzdar, Thomas Smith, J. Bergh, L. Holmberg, G. Liljegren, J. Nilsson, M. Seifert, P. Sevelda, C. Zielinsky, R. Buchanan, M. Cross, G. Royle, J. Dunn, R. Hills, M. Lee, J. Morrison, D. Spooner, A. Litton, R. Chlebowski, H. Caffier, Ebctcg (2005)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 365
-
F. Monzon, T. Koen (2010)
Diagnosis of metastatic neoplasms: molecular approaches for identification of tissue of origin.Archives of pathology & laboratory medicine, 134 2
-
M. Vijver, Yudong He, L. Veer, H. Dai, A. Hart, D. Voskuil, G. Schreiber, J. Peterse, C. Roberts, M. Marton, M. Parrish, D. Atsma, A. Witteveen, A. Glas, L. Delahaye, Tony Velde, H. Bartelink, S. Rodenhuis, E. Rutgers, S. Friend, René Bernards (2002)
A gene-expression signature as a predictor of survival in breast cancer.The New England journal of medicine, 347 25
-
S. Maheswaran, D. Haber (2010)
Circulating tumor cells: a window into cancer biology and metastasis.Current opinion in genetics & development, 20 1
-
A. Potti, H. Dressman, A. Bild, R. Riedel, G. Chan, R. Sayer, J. Cragun, H. Cottrill, M. Kelley, R. Petersen, D. Harpole, J. Marks, A. Berchuck, G. Ginsburg, P. Febbo, J. Lancaster, J. Nevins (2006)
Genomic signatures to guide the use of chemotherapeuticsNature Medicine, 12
-
T. Hudson, W. Anderson, Axel Artez, A. Barker, C. Bell, R. Bernabé, M. Bhan, F. Calvo, I. Eerola, D. Gerhard, A. Guttmacher, M. Guyer, F. Hemsley, Jennifer Jennings, D. Kerr, P. Klatt, Patrik Kolar, Jun Kusada, D. Lane, F. Laplace, Lu Youyong, G. Nettekoven, B. Ozenberger, Jane Peterson, T. Rao, J. Remacle, A. Schafer, T. Shibata, M. Stratton, J. Vockley, Koichi Watanabe, Huanming Yang, M. Yuen, B. Knoppers, M. Bobrow, A. Cambon-Thomsen, L. Dressler, S. Dyke, Y. Joly, Kazuto Kato, Karen Kennedy, Pilar Nicolàs, M. Parker, E. Rial‐Sebbag, C. Romeo-Casabona, K. Shaw, S. Wallace, G. Wiesner, N. Zeps, P. Lichter, A. Biankin, C. Chabannon, L. Chin, B. Clement, E. Álava, F. Degos, M. Ferguson, Peter Geary, D. Hayes, A. Johns, A. Kasprzyk, H. Nakagawa, R. Penny, M. Piris, R. Sarin, A. Scarpa, M. Vijver, P. Futreal, H. Aburatani, M. Bayés, David Botwell, P. Campbell, X. Estivill, S. Grimmond, I. Gut, M. Hirst, C. López-Otín, P. Majumder, M. Marra, J. McPherson, Z. Ning, X. Puente, Y. Ruan, H. Stunnenberg, H. Swerdlow, V. Velculescu, R. Wilson, H. Xue, Liu Yang, P. Spellman, Gary Bader, P. Boutros, Paul Flicek, G. Getz, R. Guigó, Guangwu Guo, D. Haussler, S. Heath, T. Hubbard, T. Jiang, Steven Jones, Qibin Li, N. López-Bigas, Ruibang Luo, L. Muthuswamy, B. Ouellette, J. Pearson, V. Quesada, Benjamin Raphael, C. Sander, T. Speed, Lincoln Stein, Joshua Stuart, J. Teague, Y. Totoki, T. Tsunoda, A. Valencia, D. Wheeler, Honglong Wu, Shancen Zhao, Guangyu Zhou, M. Lathrop, G. Thomas, Teruhiko Yoshida, M. Axton, C. Gunter, L. Miller, Junjun Zhang, Syed Haider, Jianxin Wang, C. Yung, A. Cros, Yong Liang, S. Gnaneshan, J. Guberman, J. Hsu, D. Chalmers, K. Hasel, T. Kaan, W. Lowrance, T. Masui, L. Rodriguez, C. Vergely, D. Bowtell, N. Cloonan, A. deFazio, J. Eshleman, D. Etemadmoghadam, B. Gardiner, J. Kench, R. Sutherland, M. Tempero, N. Waddell, P. Wilson, S. Gallinger, M. Tsao, P. Shaw, G. Petersen, D. Mukhopadhyay, R. DePinho, S. Thayer, K. Shazand, Timothy Beck, M. Sam, Lee Timms, Vanessa Ballin, Youyong Lu, J. Ji, Xiuqing Zhang, Feng Chen, Xueda Hu, Qi Yang, G. Tian, Lianhai Zhang, Xiaofang Xing, Xianghong Li, Zheng‐gang Zhu, Yingyan Yu, Jun Yu, J. Tost, P. Brennan, I. Holcatova, D. Zaridze, A. Brazma, L. Egevard, E. Prokhortchouk, R. Banks, M. Uhlén, Juris Viksna, F. Pontén, K. Skryabin, E. Birney, Å. Borg, A. Børresen-Dale, C. Caldas, J. Foekens, Sancha Martin, J. Reis-Filho, A. Richardson, C. Sotiriou, G. Thoms, L. Veer, D. Birnbaum, H. Blanché, Pascal Boucher, S. Boyault, Jocelyne Masson-Jacquemier, I. Pauporté, X. Pivot, A. Vincent-Salomon, E. Tabone, C. Theillet, I. Treilleux, P. Bioulac-Sage, T. Decaens, D. Franco, M. Gut, Didier Samuel, J. Zucman‐Rossi, R. Eils, B. Brors, J. Korbel, A. Korshunov, P. Landgraf, H. Lehrach, S. Pfister, B. Radlwimmer, G. Reifenberger, Michael Taylor, C. Kalle, P. Majumder, P. Pederzoli, R. Lawlor, M. Delledonne, A. Bardelli, T. Gress, D. Klimstra, G. Zamboni, Y. Nakamura, S. Miyano, Akihiro Fujimoto, E. Campo, S. Sanjosé, E. Montserrat, M. González-Díaz, P. Jares, H. Himmelbauer, S. Beà, S. Aparicio, D. Easton, F. Collins, C. Compton, E. Lander, W. Burke, A. Green, S. Hamilton, O. Kallioniemi, T. Ley, E. Liu, B. Wainwright (2010)
International network of cancer genome projectsNature, 464
-
C. Karapetis, S. Khambata-Ford, D. Jonker, C. O'Callaghan, D. Tu, N. Tebbutt, R. Simes, H. Chalchal, J. Shapiro, S. Robitaille, T. Price, L. Shepherd, H. Au, C. Langer, M. Moore, J. Zalcberg (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer.The New England journal of medicine, 359 17
-
W. Roock, D. Jonker, F. Nicolantonio, A. Sartore-Bianchi, D. Tu, S. Siena, S. Lamba, S. Arena, M. Frattini, H. Piessevaux, E. Cutsem, C. O'Callaghan, S. Khambata-Ford, J. Zalcberg, J. Simes, C. Karapetis, A. Bardelli, S. Tejpar (2010)
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.JAMA, 304 16
-
R. George, T. Sanda, M. Hanna, S. Fröhling, William Ii, Jianming Zhang, Yebin Ahn, Wenjun Zhou, W. London, Patrick McGrady, L. Xue, S. Zozulya, V. Gregor, Thomas Webb, N. Gray, D. Gilliland, L. Diller, H. Greulich, S. Morris, M. Meyerson, A. Look (2008)
Activating mutations in ALK provide a therapeutic target in neuroblastomaNature, 455
-
R. Dagher, M. Cohen, G. Williams, Mark Rothmann, J. Gobburu, G. Robbie, Atiqur Rahman, Gang Chen, Ann Staten, D. Griebel, R. Pazdur (2002)
Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.Clinical cancer research : an official journal of the American Association for Cancer Research, 8 10
-
P. Ward, Jay Patel, David Wise, O. Abdel-Wahab, Bryson Bennett, H. Coller, J. Cross, V. Fantin, C. Hedvat, A. Perl, J. Rabinowitz, M. Carroll, Shinsan Su, K. Sharp, R. Levine, C. Thompson (2010)
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.Cancer cell, 17 3
-
A. Giagounidis, U. Germing, C. Aul (2006)
Biological and Prognostic Significance of Chromosome 5q Deletions in Myeloid MalignanciesClinical Cancer Research, 12
-
AD Barker, CC Sigman, G. Kelloff, N. Hylton, D. Berry, L. Esserman (2009)
I‐SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant ChemotherapyClinical Pharmacology & Therapeutics, 86
-
J. Andersen, S. Sathyanarayanan, A. Bacco, An Chi, Theresa Zhang, A. Chen, B. Dolinski, M. Kraus, Brian Roberts, W. Arthur, R. Klinghoffer, D. Gargano, Lixia Li, I. Feldman, Bethany Lynch, J. Rush, R. Hendrickson, P. Blume-Jensen, C. Paweletz (2010)
Pathway-Based Identification of Biomarkers for Targeted Therapeutics: Personalized Oncology with PI3K Pathway InhibitorsScience Translational Medicine, 2
-
S. Khambata-Ford, C. Garrett, N. Meropol, M. Basik, C. Harbison, Shujian Wu, T. Wong, Xin Huang, C. Takimoto, A. Godwin, B. Tan, S. Krishnamurthi, H. Burris, E. Poplin, M. Hidalgo, J. Baselga, E. Clark, D. Mauro (2007)
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 22
-
K. Baggerly, K. Coombes (2009)
Deriving chemosensitivity from cell lines: Forensic bioinformatics and reproducible research in high-throughput biologyThe Annals of Applied Statistics, 3
-
M. Li, F. Diehl, D. Dressman, B. Vogelstein, K. Kinzler (2006)
BEAMing up for detection and quantification of rare sequence variantsNature Methods, 3
-
Clark Gm, William McGuire, Hubay Ca, Pearson Oh, Carter Ac (1983)
The importance of estrogen and progesterone receptor in primary breast cancer.Progress in clinical and biological research, 132E
-
Kimberly Wiegand, Sohrab Shah, Osama Al-Agha, Yongjun Zhao, Kane Tse, Thomas Zeng, J. Senz, M. Mcconechy, M. Anglesio, S. Kalloger, Winnie Yang, A. Heravi‐Moussavi, Ryan Giuliany, C. Chow, J. Fee, Abdalnasser Zayed, Leah Prentice, Nataliya Melnyk, G. Turashvili, Allen Delaney, J. Madore, S. Yip, A. McPherson, G. Ha, Lynda Bell, S. Fereday, Angela Tam, L. Galletta, P. Tonin, D. Provencher, Dianne Miller, Steven Jones, Richard Moore, G. Morin, A. Oloumi, Niki Boyd, S. Aparicio, I. Shih, A. Mes-Masson, D. Bowtell, M. Hirst, B. Gilks, M. Marra, D. Huntsman (2010)
ARID1A mutations in endometriosis-associated ovarian carcinomas.The New England journal of medicine, 363 16
-
B. Taylor, N. Schultz, H. Hieronymus, A. Gopalan, Yonghong Xiao, B. Carver, V. Arora, Poorvi Kaushik, E. Cerami, B. Reva, Yevgeniy Antipin, N. Mitsiades, Thomas Landers, Igor Dolgalev, John Major, Manda Wilson, N. Socci, A. Lash, A. Heguy, J. Eastham, H. Scher, V. Reuter, P. Scardino, C. Sander, C. Sawyers, W. Gerald (2010)
Integrative genomic profiling of human prostate cancer.Cancer cell, 18 1
-
R. Kralovics, F. Passamonti, A. Buser, Soon-Siong Teo, R. Tiedt, J. Passweg, A. Tichelli, M. Cazzola, R. Skoda (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders.The New England journal of medicine, 352 17
-
A. Hochhaus, M. Baccarani, M. Deininger, J. Apperley, J. Lipton, S. Goldberg, S. Corm, N. Shah, F. Cervantes, R. Silver, D. Niederwieser, R. Stone, H. Dombret, R. Larson, L. Roy, T. Hughes, M. Müller, R. Ezzeddine, A. Countouriotis, H. Kantarjian (2008)
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinibLeukemia, 22
-
D. Slamon, B. Leyland-Jones, Steven Shak, Hank Fuchs, Virginia Paton, A. Bajamonde, Thomas Fleming, W. Eiermann, Janet Wolter, M. Pegram, J. Baselga, Larry Norton (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.The New England journal of medicine, 344 11
-
L. Dang, D. White, S. Gross, Bryson Bennett, M. Bittinger, E. Driggers, V. Fantin, H. Jang, Shengfang Jin, M. Keenan, K. Marks, R. Prins, P. Ward, K. Yen, L. Liau, J. Rabinowitz, L. Cantley, C. Thompson, M. Heiden, Shinsan Su (2010)
Cancer-associated IDH1 mutations produce 2-hydroxyglutarateNature, 465
-
S. Paik, S. Shak, G. Tang, Chungyeul Kim, J. Baker, M. Cronin, F. Baehner, M. Walker, D. Watson, T. Park, W. Hiller, E. Fisher, D. Wickerham, J. Bryant, N. Wolmark, Genomic Health, Redwood City, S. Francisco (2004)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.The New England journal of medicine, 351 27
-
U. McDermott, Sreenath Sharma, L. Dowell, Patricia Greninger, C. Montagut, Jennifer Lamb, H. Archibald, Raul Raudales, Angela Tam, Diana Lee, S. Rothenberg, J. Supko, Raffaella Sordella, L. Ulkus, A. Iafrate, S. Maheswaran, C. Njauw, H. Tsao, L. Drew, J. Hanke, Xiao-Jun Ma, M. Erlander, N. Gray, D. Haber, J. Settleman (2007)
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profilingProceedings of the National Academy of Sciences, 104
-
D. Hoff, P. LoRusso, C. Rudin, J. Reddy, R. Yauch, R. Tibes, G. Weiss, M. Borad, C. Hann, J. Brahmer, H. Mackey, B. Lum, W. Darbonne, J. Marsters, F. Sauvage, J. Low (2009)
Inhibition of the hedgehog pathway in advanced basal-cell carcinoma.The New England journal of medicine, 361 12
-
S. Joosse, K. Brandwijk, P. Devilee, J. Wesseling, F. Hogervorst, S. Verhoef, P. Nederlof (2012)
Prediction of BRCA2-association in hereditary breast carcinomas using array-CGHBreast Cancer Research and Treatment, 132
-
IB Weinstein (2002)
Cancer. Addiction to oncogenes—the Achilles heal of cancerScience, 297
-
E. Mardis, L. Ding, D. Dooling, D. Larson, M. McLellan, Ken Chen, D. Koboldt, R. Fulton, K. Delehaunty, S. McGrath, L. Fulton, D. Locke, V. Magrini, R. Abbott, T. Vickery, Jerry Reed, J. Robinson, T. Wylie, Scott Smith, Lynn Carmichael, James Eldred, C. Harris, Jason Walker, Joshua Peck, Feiyu Du, Adam Dukes, Gabriel Sanderson, Anthony Brummett, Eric Clark, Joshua McMichael, R. Meyer, Jonathan Schindler, C. Pohl, J. Wallis, Xiaoqi Shi, Ling Lin, Heather Schmidt, Yuzhu Tang, C. Haipek, Madeline Wiechert, Jolynda Ivy, Joelle Kalicki, Glendoria Elliott, R. Ries, J. Payton, P. Westervelt, M. Tomasson, M. Watson, J. Baty, S. Heath, W. Shannon, R. Nagarajan, D. Link, M. Walter, T. Graubert, J. Dipersio, R. Wilson, T. Ley (2009)
Recurring mutations found by sequencing an acute myeloid leukemia genome.The New England journal of medicine, 361 11
-
B. Spurrier, S. Ramalingam, S. Nishizuka (2008)
Reverse-phase protein lysate microarrays for cell signaling analysisNature Protocols, 3
-
M. Hölzel, Sidong Huang, J. Koster, I. Øra, Arjan Lakeman, H. Caron, Wouter Nijkamp, Jing Xie, T. Callens, S. Asgharzadeh, R. Seeger, L. Messiaen, R. Versteeg, R. Bernards (2010)
NF1 Is a Tumor Suppressor in Neuroblastoma that Determines Retinoic Acid Response and Disease OutcomeCell, 142
-
M. Moroni, A. Sartore-Bianchi, S. Benvenuti, S. Artale, A. Bardelli, S. Siena (2005)
Somatic mutation of EGFR catalytic domain and treatment with gefitinib in colorectal cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 16 11
-
S. Gross, R. Cairns, M. Minden, E. Driggers, M. Bittinger, H. Jang, M. Sasaki, Shengfang Jin, D. Schenkein, Shinsan Su, L. Dang, V. Fantin, T. Mak (2010)
Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutationsThe Journal of Experimental Medicine, 207
-
C. James, V. Ugo, J. Couédic, J. Staerk, F. Delhommeau, C. Lacout, L. Garçon, H. Raslova, R. Berger, A. Bennaceur-Griscelli, J. Villeval, S. Constantinescu, N. Casadevall, W. Vainchenker (2005)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 434
-
Nathan Ihle, Robert Lemos, P. Wipf, A. Yacoub, Clint Mitchell, D. Siwak, G. Mills, P. Dent, D. Kirkpatrick, G. Powis (2009)
Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance.Cancer research, 69 1
-
A. Kuilenburg, R. Meinsma, L. Zoetekouw, A. Gennip (2002)
Increased risk of grade IV neutropenia after administration of 5‐fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: High prevalence of the IVS14+1g>a mutationInternational Journal of Cancer, 101
-
Siân Jones, Tian-Li Wang, I. Shih, T. Mao, K. Nakayama, R. Roden, Ruth Glas, D. Slamon, L. Diaz, B. Vogelstein, K. Kinzler, V. Velculescu, N. Papadopoulos (2010)
Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell CarcinomaScience, 330
-
R. Leary, Isaac Kinde, F. Diehl, Kerstin Schmidt, C. Clouser, C. Duncan, A. Antipova, Clarence Lee, K. McKernan, Francisco Vega, K. Kinzler, B. Vogelstein, L. Diaz, V. Velculescu (2010)
Development of Personalized Tumor Biomarkers Using Massively Parallel SequencingScience Translational Medicine, 2
-
P. Eichhorn, M. Gili, M. Scaltriti, V. Serra, M. Guzman, Wouter Nijkamp, R. Beijersbergen, Vanesa Valero, J. Seoane, R. Bernards, J. Baselga (2008)
Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.Cancer research, 68 22
-
M Maemondo (2010)
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFRN. Engl. J. Med., 362
-
L. Tanoue (2011)
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFRYearbook of Pulmonary Disease, 2011
-
F. Cardoso, L. Veer, E. Rutgers, S. Loi, S. Mook, M. Piccart-Gebhart (2008)
Clinical application of the 70-gene profile: the MINDACT trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 5
-
M. Soda, Y. Choi, M. Enomoto, S. Takada, Y. Yamashita, S. Ishikawa, Shin-ichiro Fujiwara, Hideki Watanabe, K. Kurashina, H. Hatanaka, M. Bando, S. Ohno, Y. Ishikawa, H. Aburatani, T. Niki, Y. Sohara, Y. Sugiyama, H. Mano (2007)
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancerNature, 448
-
J. Singer, Y. Shou, F. Giles, H. Kantarjian, Yi-Hsiang Hsu, A. Robeva, Patricia Rae, A. Weitzman, J. Meyer, M. Dugan, O. Ottmann (2007)
UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemiaLeukemia, 21
-
J. Engelman (2009)
Targeting PI3K signalling in cancer: opportunities, challenges and limitationsNature Reviews Cancer, 9
-
Meng-er Huang, Yu-chen Ye, Shu-rong Chen, Jingren Chai, Jia-xiang Lu, Zhao Lin, L. Gu, Zhen-yi Wang (1988)
Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia.Haematology and blood transfusion, 32
-
F. Ducray, Y. Marie, M. Sanson (2009)
IDH1 and IDH2 mutations in gliomas.The New England journal of medicine, 360 21
-
F. Diehl, Kerstin Schmidt, M. Choti, K. Romans, S. Goodman, M. Li, K. Thornton, N. Agrawal, L. Sokoll, Steve Szabo, K. Kinzler, B. Vogelstein, L. Diaz (2008)
Circulating mutant DNA to assess tumor dynamicsNature Medicine, 14
-
G. Marcucci, K. Maharry, Yue-zhong Wu, M. Radmacher, K. Mrózek, D. Margeson, Kelsi Holland, S. Whitman, H. Becker, S. Schwind, K. Metzeler, B. Powell, T. Carter, J. Kolitz, M. Wetzler, A. Carroll, M. Baer, M. Caligiuri, R. Larson, C. Bloomfield (2010)
IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 14
-
B. Druker, M. Talpaz, D. Resta, B. Peng, E. Buchdunger, J. Ford, N. Lydon, H. Kantarjian, R. Capdeville, Sayuri Ohno-Jones, C. Sawyers (2001)
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.The New England journal of medicine, 344 14
-
G. Bollag, P. Hirth, J. Tsai, Jiazhong Zhang, P. Ibrahim, Hanna Cho, W. Spevak, Chao Zhang, Ying Zhang, G. Habets, Elizabeth Burton, B. Wong, Garson Tsang, B. West, Ben Powell, Rafe Shellooe, A. Marimuthu, Hoa Nguyen, Kam Zhang, D. Artis, J. Schlessinger, F. Su, B. Higgins, R. Iyer, K. D’Andrea, A. Koehler, M. Stumm, P. Lin, Richard Lee, J. Grippo, I. Puzanov, Kevin Kim, A. Ribas, G. McArthur, J. Sosman, P. Chapman, K. Flaherty, Xiaowei Xu, K. Nathanson, K. Nolop (2010)
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaNature, 467
-
F. Nicolantonio, M. Martini, F. Molinari, A. Sartore-Bianchi, S. Arena, P. Saletti, S. Dosso, L. Mazzucchelli, M. Frattini, S. Siena, A. Bardelli (2008)
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 35
-
K. Coombes, Jing Wang, K. Baggerly (2007)
Microarrays: retracing stepsNature Medicine, 13
-
I. Janoueix-Lerosey, D. Lequin, L. Brugières, A. Ribeiro, L. Pontual, V. Combaret, V. Raynal, A. Puisieux, G. Schleiermacher, G. Pierron, D. Valteau‐Couanet, T. Frebourg, J. Michon, S. Lyonnet, J. Amiel, O. Delattre (2008)
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastomaNature, 455
-
R. Amado, M. Wolf, M. Peeters, E. Cutsem, S. Siena, Daniel Freeman, T. Juan, R. Sikorski, S. Suggs, R. Radinsky, S. Patterson, David Chang (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 10
-
H. Davies, G. Bignell, Charles Cox, P. Stephens, S. Edkins, S. Clegg, J. Teague, H. Woffendin, Mathew Garnett, W. Bottomley, Neil Davis, E. Dicks, Rebecca Ewing, Yvonne Floyd, K. Gray, S. Hall, R. Hawes, Jaime Hughes, Vivian Kosmidou, A. Menzies, Catherine Mould, A. Parker, C. Stevens, S. Watt, S. Hooper, Rebecca Wilson, H. Jayatilake, B. Gusterson, C. Cooper, J. Shipley, D. Hargrave, K. Pritchard-Jones, N. Maitland, G. Chenevix-Trench, G. Riggins, D. Bigner, G. Palmieri, A. Cossu, A. Flanagan, A. Nicholson, Judy Ho, Suet Leung, Siu Yuen, Barbara Weber, H. Seigler, T. Darrow, H. Paterson, R. Marais, Christopher Marshall, R. Wooster, Michael Stratton, P. Futreal (2002)
Mutations of the BRAF gene in human cancerNature, 417
-
T. Fojo, C. Grady (2009)
How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question.Journal of the National Cancer Institute, 101 15
-
William Lee, Zhaoshi Jiang, Jinfeng Liu, Peter Haverty, Y. Guan, Jeremy Stinson, Peng Yue, Yan Zhang, K. Pant, Deepali Bhatt, Connie Ha, Stephanie Johnson, M. Kennemer, S. Mohan, Igor Nazarenko, C. Watanabe, A. Sparks, D. Shames, R. Gentleman, F. Sauvage, H. Stern, A. Pandita, D. Ballinger, R. Drmanac, Z. Modrušan, S. Seshagiri, Zemin Zhang (2010)
The mutation spectrum revealed by paired genome sequences from a lung cancer patientNature, 465
-
I. Astsaturov, V. Ratushny, A. Sukhanova, M. Einarson, T. Bagnyukova, Yan Zhou, K. Devarajan, J. Silverman, Nadezhda Tikhmyanova, N. Skobeleva, A. Pecherskaya, Rochelle Nasto, Catherine Sharma, S. Jablonski, I. Serebriiskii, L. Weiner, E. Golemis (2010)
Synthetic Lethal Screen of an EGFR-Centered Network to Improve Targeted TherapiesScience Signaling, 3
-
M. Hazarika, Xiaoping Jiang, Qi Liu, Shwu-Luan Lee, R. Ramchandani, C. Garnett, M. Orr, R. Sridhara, B. Booth, J. Leighton, W. Timmer, R. Harapanhalli, R. Dagher, R. Justice, R. Pazdur (2008)
Tasigna for Chronic and Accelerated Phase Philadelphia Chromosome–Positive Chronic Myelogenous Leukemia Resistant to or Intolerant of ImatinibClinical Cancer Research, 14
-
Yuyan Chen, J. Takita, Y. Choi, Motohiro Kato, M. Ohira, M. Sanada, Lili Wang, M. Soda, A. Kikuchi, T. Igarashi, A. Nakagawara, Y. Hayashi, H. Mano, S. Ogawa (2008)
Oncogenic mutations of ALK kinase in neuroblastomaNature, 455
-
A. Bild, Guang Yao, Jeffrey Chang, Quanli Wang, A. Potti, D. Chasse, M. Joshi, D. Harpole, J. Lancaster, A. Berchuck, J. Olson, J. Marks, H. Dressman, M. West, J. Nevins (2006)
Oncogenic pathway signatures in human cancers as a guide to targeted therapiesNature, 439
-
F. Santos, H. Kantarjian, N. Jain, T. Manshouri, D. Thomas, G. Garcia-Manero, Deborah Kennedy, Z. Estrov, J. Cortes, S. Verstovsek (2010)
Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.Blood, 115 6
-
H. Farmer, N. Mccabe, C. Lord, A. Tutt, Damian Johnson, T. Richardson, M. Santarosa, Krystyna Dillon, I. Hickson, C. Knights, N. Martin, S. Jackson, G. Smith, A. Ashworth (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature, 434
-
B. Marty, V. Maire, E. Gravier, G. Rigaill, A. Vincent-Salomon, Marion Kappler, I. Lebigot, Fathia Djelti, Audrey Tourdès, P. Gestraud, P. Hupé, E. Barillot, F. Cruzalegui, G. Tucker, M. Stern, J. Thiery, J. Hickman, T. Dubois (2008)
Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cellsBreast Cancer Research : BCR, 10
-
L. Veer, H. Dai, M. Vijver, Yudong He, A. Hart, M. Mao, H. Peterse, K. Kooy, M. Marton, A. Witteveen, G. Schreiber, R. Kerkhoven, C. Roberts, P. Linsley, R. Bernards, S. Friend (2002)
Gene expression profiling predicts clinical outcome of breast cancerNature, 415
-
G. Noël, Mazeron Jj (2001)
[Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials].Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 5 1
-
Anurag Singh, Patricia Greninger, D. Rhodes, L. Koopman, S. Violette, N. Bardeesy, J. Settleman (2009)
A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival.Cancer cell, 15 6
-
C. Niu, Hua Yan, Yu Ting, Huiping Sun, Jian-Xiang Liu, Xiu-Song Li, Wen Wu, Fen-Qin Zhang, Yú Chen, Li Zhou, Junmin Li, X. Zeng, Ren-Rong Yang, Mi-Man Yuan, Mei-Yu Ren, Feng-Ying Gu, Q. Cao, B. Gu, X. Su, Guo-Qiang Chen, S. Xiong, Ting-Dong Zhang, Samuel Waxman, Zhen-yi Wang, Zhu Chen, Jiong Hu, Z. Shen, Sai-Juan Chen (1999)
Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients.Blood, 94 10
-
E. Baxter, L. Scott, P. Campbell, C. East, N. Fourouclas, S. Swanton, G. Vassiliou, A. Bench, E. Boyd, N. Curtin, M. Scott, W. Erber, A. Green (2005)
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disordersThe Lancet, 365
-
E. Kwak, Y. Bang, D. Camidge, A. Shaw, B. Solomon, Robert Maki, Sai-Hong Ou, Bruce Dezube, P. Jänne, Daniel, B. Costa, M. Varella-Garcia, W. Kim, Thomas Lynch, P. Fidias, Hannah Stubbs, J. Engelman, V. Lecia, Sequist, Weiwei Tan, L. Gandhi, M. Mino‐Kenudson, Greg Wei, S. Shreeve, M. Ratain, Jeffrey, Settleman, James Christensen, D. Haber, K. Wilner, R. Salgia, Geoffrey Shapiro, J. Clark, A. Iafrate (2010)
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.The New England journal of medicine, 363 18
-
T. Ley, E. Mardis, L. Ding, B. Fulton, M. McLellan, Ken Chen, D. Dooling, Brian Dunford-Shore, S. McGrath, M. Hickenbotham, L. Cook, R. Abbott, D. Larson, D. Koboldt, C. Pohl, Scott Smith, Amy Hawkins, S. Abbott, D. Locke, L. Hillier, T. Miner, L. Fulton, V. Magrini, T. Wylie, Jarret Glasscock, J. Conyers, Nathan Sander, Xiaoqi Shi, John Osborne, P. Minx, D. Gordon, A. Chinwalla, Yu Zhao, R. Ries, J. Payton, P. Westervelt, M. Tomasson, M. Watson, J. Baty, J. Ivanovich, S. Heath, W. Shannon, R. Nagarajan, M. Walter, D. Link, T. Graubert, J. Dipersio, R. Wilson (2008)
DNA sequencing of a cytogenetically normal acute myeloid leukemia genomeNature, 456
-
P. Ravdin, S. Green, T Dorr, W McGuire, C. Fabian, R. Pugh, R. Carter, S. Rivkin, J. Borst, R. Belt (1992)
Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 10 8
-
S. Hanash, A. Taguchi (2010)
The grand challenge to decipher the cancer proteomeNature Reviews Cancer, 10
-
W. Kaelin (2005)
The Concept of Synthetic Lethality in the Context of Anticancer TherapyNature Reviews Cancer, 5
-
I. Weinstein (2002)
Addiction to Oncogenes--the Achilles Heal of CancerScience, 297
-
S. Joosse, E. Beers, Ivon Tielen, H. Horlings, J. Peterse, N. Hoogerbrugge, M. Ligtenberg, L. Wessels, Priscilla Axwijk, S. Verhoef, F. Hogervorst, P. Nederlof (2008)
Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGHBreast Cancer Research and Treatment, 116
- Publisher
- Springer Journals
- Copyright
- Copyright © 2011 by Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.
- Subject
- Biomedicine; Biomedicine, general; Cancer Research; Metabolic Diseases; Infectious Diseases; Molecular Medicine; Neurosciences
- ISSN
- 1078-8956
- eISSN
- 1546-170X
- DOI
- 10.1038/nm.2311
- Publisher site
- See Article on Publisher Site
Abstract
The gradual shift from cytotoxic drugs to highly selective, targeted therapeutic agents for cancer requires a parallel effort to characterize cancers at the molecular level to guide the choice of therapy for the individual patient. Here we review the genomic technologies that can be used to develop these drug response indicators, or biomarkers. We also discuss hurdles in their development and the implementation of biomarkers in clinical practice.
Journal
Nature Medicine – Springer Journals
Published: Mar 7, 2011